Bextra On Capitol Hill: FDA’s “Turning Point” Or Another Sign Of Failure?
Executive Summary
FDA's request for Pfizer to withdraw the COX-2 inhibitor Bextra could signal a new era of strong decision making at FDA, Senate Finance Committee Chairman Charles Grassley (R-Iowa) declared